1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Lipid Disorders Global Clinical Trials Review, H2, 2015

Lipid Disorders Global Clinical Trials Review, H2, 2015

  • December 2015
  • -
  • Global Data
  • -
  • 970 pages

Lipid Disorders Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Lipid Disorders Global Clinical Trials Review, H2, 2015" provides an overview of Lipid Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Lipid Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Lipid Disorders Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Lipid Disorders to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Lipid Disorders to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Lipid Disorders Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 967
Abbreviations 967
Definitions 967
Research Methodology 968
Secondary Research 968
About GlobalData 969
Contact Us 969
Disclaimer 969
Source 970

List of Tables
Lipid Disorders Therapeutics, Global, Clinical Trials by Region, 2015* 6
Lipid Disorders Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Lipid Disorders Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Lipid Disorders Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Lipid Disorders Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Lipid Disorders Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Lipid Disorders Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Lipid Disorders Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 14
Proportion of Lipid Disorders to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Lipid Disorders Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Lipid Disorders Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Lipid Disorders to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 18
Lipid Disorders Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Lipid Disorders Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Lipid Disorders Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Lipid Disorders Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Lipid Disorders Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Lipid Disorders Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Lipid Disorders Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Lipid Disorders Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Lipid Disorders Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Lipid Disorders Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Lipid Disorders Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures
Lipid Disorders Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Lipid Disorders Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Lipid Disorders Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Lipid Disorders Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Lipid Disorders Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Lipid Disorders Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Lipid Disorders Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Lipid Disorders Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 14
Proportion of Lipid Disorders to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Lipid Disorders Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Lipid Disorders Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Lipid Disorders to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 18
Lipid Disorders Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Lipid Disorders Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Lipid Disorders Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Lipid Disorders Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Lipid Disorders Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Lipid Disorders Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Lipid Disorders Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Lipid Disorders Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
Lipid Disorders Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Lipid Disorders Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Lipid Disorders Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 968

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.